Psilocybin Side Effects and Safety: What Patients Need to Know

Supervised psilocybin-assisted therapy has a well-characterised acute side-effect profile: transient nausea, brief blood-pressure and heart-rate rises, mild headache, fatigue, and the intensity of the psychedelic experience itself, which can include anxiety or challenging emotional content. Serious adverse events are rare in published trials. Several absolute contraindications, including personal or family history of psychotic disorder, concurrent lithium, and uncontrolled cardiovascular disease, make pre-treatment screening essential before any clinical psilocybin session.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334, 2026-05-27.

Key takeaways

• Most acute side effects resolve within the dosing day or within 24 hours afterward.
• Challenging experiences (fear, grief, disorientation) are common, often productive, and are managed by the therapy team.
• Absolute contraindications include: personal history of psychotic disorder, first-degree family history of psychotic disorder, active or recent mania, uncontrolled cardiovascular disease, current pregnancy, and concurrent lithium (seizure case reports).
• Concurrent lithium is a firm exclusion. High-dose SSRIs and tramadol require specific clinical discussion before any session.
• Long-term safety data at therapeutic doses is limited but encouraging; no persistent harms documented across published trial follow-ups.
• Hallucinogen Persisting Perception Disorder (HPPD) is rare in clinical settings; most case reports involve recreational chronic use.
• Legal patient access to psilocybin in Canada requires Health Canada authorization on a case-by-case basis, initiated by a physician. The supervised clinical setting and pre-treatment screening that accompany this authorized access are central to this safety profile.

If you have safety or eligibility questions, book a free 15-minute information call with ATMA CENA's clinical team.

---

What acute side effects can I expect during and after a session?

Supervised psilocybin produces a predictable set of short-term effects. Most resolve within the dosing day or within 24 hours.

Nausea and stomach upset. Mild-to-moderate nausea occurs in roughly half of psilocybin sessions in published trials, especially during onset as the drug absorbs. It usually settles within one to two hours. Some protocols use a light pre-dose fast or anti-emetics to reduce the risk. Vomiting is less common and rarely persists beyond the onset period.

Transient blood-pressure and heart-rate rise. Psilocybin raises sympathetic tone. Blood pressure and heart rate typically rise 10 to 20 percent from baseline during the session and return to normal within one to two hours of comedown. This is one reason cardiovascular screening is mandatory before dosing; see the contraindications section below.

Headache. Mild-to-moderate headache during the session or in the hours afterward is common. Rest, hydration, and standard over-the-counter analgesia are usually sufficient. A severe or persistent headache should be reported to your prescribing physician.

Fatigue. Most patients feel emotionally and physically tired for 24 to 48 hours after a session. This is normal and reflects the intensity of the experience.

Mild visual after-effects. Slightly enhanced colours or brief afterimages sometimes persist for hours to days after dosing. Persistent visual disturbances lasting more than a week are uncommon in clinical settings; see the HPPD section below.

Challenging experiences during dosing

A meaningful share of sessions include moments of intense fear, grief, body discomfort, or disorientation. The clinical literature labels these "challenging experiences" rather than "bad trips," and they are not failures. Research by [Carbonaro et al. 2016, J Psychopharmacol, PMID 27578767] surveyed nearly 2,000 people about their most difficult psilocybin experience and found that 84 percent reported a net long-term benefit, even when the acute content was distressing. Fewer than 1 percent developed lasting harm.

In a supervised clinical session, the therapy team holds non-directive presence during peak intensity and supports grounding when needed. Integration sessions in the days and weeks that follow are where challenging content is processed and given meaning. Most challenging experiences become productive parts of the therapeutic work rather than obstacles to it.

---

What are the contraindications for psilocybin therapy?

The exclusions below reflect pre-treatment screening criteria used across the major published psilocybin trials. Pre-treatment screening at the prescribing-physician level is standard practice on the authorized-access pathway and applies before any session.

Absolute contraindications

Contraindication	Reason
Personal history of psychotic disorder (schizophrenia, schizoaffective, bipolar I with psychosis)	Risk of precipitating or worsening psychosis
First-degree family history of psychotic disorder	Genetic vulnerability to psychosis-spectrum reactions
Active mania or recent hypomania (typically within 3 months)	Risk of destabilisation
Uncontrolled cardiovascular disease: recent MI within 6 months, severe structural heart disease, unstable angina, significant arrhythmia	Cardiovascular effects of psilocybin (BP and HR rise)
Current pregnancy	Insufficient safety data; theoretical foetal risk
Concurrent lithium	Seizure case reports in combination with psilocybin

Relative contraindications (clinical case-by-case)

Contraindication	Reason
Active suicidal ideation requiring acute psychiatric care	Acute crisis requires stabilisation before any psychedelic work
Severe personality disorder with marked instability	May require longer stabilisation and structured prep before dosing
Active substance use disorder requiring stabilisation	Concurrent instability complicates dosing safety
Concurrent high-dose serotonergic antidepressants (SSRIs, SNRIs)	Theoretical serotonin syndrome risk; may also blunt the psychedelic response, so taper planning is often required
Tramadol	Serotonin syndrome risk with psilocybin; flag before dosing
Cognitive impairment affecting informed consent	Informed consent is required for any authorized session

Well-controlled hypertension on appropriate medication, lower-dose serotonergic antidepressants, and most standard cardiovascular medications are generally compatible with appropriate clinical oversight. The prescribing physician determines this at intake.

---

What about drug interactions?

Lithium, firm exclusion. Case reports describe seizures when lithium and psilocybin are used together. Most clinical protocols treat this as an absolute contraindication. Patients on lithium who are pursuing authorized psilocybin access can only proceed after a carefully managed taper under prescriber supervision, if at all.

MAOIs (monoamine oxidase inhibitors). Theoretical risk of serotonergic crisis. MAOIs are typically excluded from clinical psilocybin protocols.

High-dose SSRIs and SNRIs. Chronic high-dose SSRI use can blunt psilocybin's effects through 5-HT2A receptor adaptation. There is also a theoretical serotonin syndrome risk at higher doses, though this is rare at clinical doses. Many published trial protocols taper SSRIs before dosing under prescriber supervision. The specific approach is decided with the prescribing physician; it is not a blanket exclusion, but it requires planning.

Tramadol. Carries a serotonin syndrome risk with serotonergic agents including psilocybin. Flag with your prescribing physician and your pain provider before any psilocybin session.

Benzodiazepines. May attenuate psilocybin's effect. Many protocols hold benzodiazepines on dosing day. Not always a hard exclusion, but a meaningful pharmacodynamic consideration.

Standard cardiovascular medications, gabapentin, pregabalin, and most opioids (excluding tramadol) are generally compatible with appropriate cardiac screening.

---

What does long-term safety look like?

Long-term safety data at therapeutic supervised doses is limited but consistent. The largest published follow-up is [Agin-Liebes et al. 2020, J Psychopharmacol, PMID 31916890], a four- to five-year follow-up of the Ross 2016 NYU cancer-distress cohort. No late-emerging psychiatric or medical concerns were found; no cases of HPPD, persistent psychosis, or substance use disorder emerged.

Other published follow-ups, including Carhart-Harris 2018 at six months [PMID 29119217], Davis 2021 at one year [PMID 33146667], and Bogenschutz 2022 [JAMA Psychiatry, PMID 36001306] over 32 weeks, similarly found no persistent harms.

The clinical-recreational distinction matters. Most safety concerns in older literature reflect recreational chronic high-dose use. Therapeutic supervised single- or two-dose protocols delivered under authorized clinical conditions have a substantially different profile: screened patients, pharmaceutical-grade drug from a licensed producer, medically supervised dosing environment, and structured integration support.

Sample sizes in published trials remain small relative to long-term data for established psychiatric medications, and observational data from real-world authorized-access populations is early-stage. The honest position: long-term safety is encouraging, not proven at scale.

---

What is HPPD and how common is it in clinical settings?

Hallucinogen Persisting Perception Disorder (HPPD) involves persistent visual disturbances (visual snow, geometric patterns, palinopsia) lasting weeks to months after psychedelic use.

In authorized clinical settings, HPPD has not emerged as a significant concern across published trials. The Agin-Liebes 2020 four- to five-year follow-up found no HPPD cases. Most published HPPD case reports involve recreational chronic use, often combined with cannabis or other substances.

HPPD is typically self-limiting; most cases resolve without specific treatment. If you notice persistent visual changes more than one week after a psilocybin session, contact your prescribing physician.

---

What symptoms after a session should prompt urgent attention?

Most post-session symptoms resolve within 24 to 48 hours. Contact your prescribing physician or emergency services for:

• Persistent disorientation or confusion more than four to six hours after the session ends
• Sustained elevated blood pressure not resolving one to two hours after dosing
• Severe headache uncontrolled by rest, hydration, or standard analgesia
• Chest pain, shortness of breath, or palpitations
• Severe persistent nausea or vomiting beyond six hours
• Worsening mood or new or worsening suicidal ideation in the 24 to 72 hours following the session
• Persistent visual disturbances lasting more than one week
• Persistent severe anxiety not resolving within 48 hours

For acute psychiatric crisis, call 9-8-8 (Canada Suicide Crisis Helpline) or go to your nearest emergency department.

---

Frequently asked questions

Is psilocybin therapy safe?

In supervised clinical settings with appropriate pre-treatment screening, the safety profile is well-characterised. Most side effects are transient and resolve within hours to days. Serious adverse events in published trials have been rare. Long-term data is limited but encouraging; no persistent harms have been documented across published follow-ups of supervised therapeutic protocols.

What are the most common side effects?

Mild-to-moderate nausea, transient blood-pressure elevation, mild headache, fatigue, and the intensity of the psychedelic experience itself, which can include challenging emotional content. Most resolve within the dosing day or within 24 hours.

Can I take psilocybin if I am on an SSRI?

This is a clinical decision made with your prescribing physician. Many trial protocols taper SSRIs before dosing under supervision because chronic high-dose SSRIs may blunt the response and carry a theoretical serotonin-syndrome risk. The specific approach is individualized based on dose, duration, and clinical context.

Can I take psilocybin if I am on lithium?

Concurrent lithium is treated as an absolute contraindication due to seizure case reports. Patients on lithium who are pursuing authorized psilocybin access can only proceed after a carefully managed taper under prescriber supervision, if at all. This is not a relative caution; it is a firm exclusion in published clinical protocols.

What about tramadol?

Tramadol carries a serotonin syndrome risk with psilocybin and is flagged as a meaningful interaction in clinical screening. Discuss this with your prescribing physician and your pain provider before any psilocybin session.

What if I have a difficult experience during the session?

Difficult experiences (fear, grief, body discomfort, disorientation) are common and often productive. Research by Carbonaro et al. 2016 found that 84 percent of people who described their most difficult psilocybin experience reported long-term benefit from it. The therapy team holds non-directive presence during the session; integration sessions afterward are where challenging content is processed. These experiences are not treatment failures.

Is HPPD a real risk in clinical settings?

HPPD is rare in authorized clinical settings. No cases were found in the Agin-Liebes 2020 four- to five-year follow-up. Most published HPPD case reports involve recreational chronic use, often with cannabis or other substances. HPPD is typically self-limiting. If you experience persistent visual changes more than one week after a session, contact your prescribing physician.

Will psilocybin trigger psychosis?

Personal and first-degree family history of psychotic disorder are absolute contraindications precisely because of this risk. In screened populations without these risk factors, psychosis emerging from clinical supervised psilocybin has been very rare across published trials.

What about heart disease?

Pre-treatment cardiovascular screening is essential. Recent MI within six months, severe structural heart disease, unstable angina, and significant arrhythmia are absolute contraindications. Well-controlled hypertension on appropriate medication is generally compatible with clinical oversight.

Will I become dependent on psilocybin?

Psilocybin has very low abuse potential compared to most controlled substances. Single- or two-dose supervised clinical protocols do not create exposure conditions associated with dependence. Regulatory requirements on the authorized-access pathway also do not permit take-home dispensing.

---

Regulatory access and compliance

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Legal patient access to psilocybin-assisted therapy requires Health Canada authorization on a case-by-case basis, initiated by a physician, and is not guaranteed. This authorized access is primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. For MDMA, authorization is primarily granted for adults with PTSD.

Nothing in this article constitutes a clinical recommendation for a specific individual. Clinical and prescribing decisions belong with a qualified physician who can assess your specific medical history, current medications, and eligibility for authorized access.

---

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

---

Sources

1. Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms. J Psychopharmacol, 30(12):1268–1278. PMID 27578767. https://pubmed.ncbi.nlm.nih.gov/27578767/
2. Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol, 34(2):155–166. PMID 31916890. https://pubmed.ncbi.nlm.nih.gov/31916890/
3. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2):399–408. PMID 29119217. https://pubmed.ncbi.nlm.nih.gov/29119217/
4. Davis AK, Barrett FS, May DG, et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry, 78(5):481–489. PMID 33146667. https://pubmed.ncbi.nlm.nih.gov/33146667/
5. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. NEJM, 387(18):1637–1648. PMID 36322843. https://pubmed.ncbi.nlm.nih.gov/36322843/
6. Bogenschutz MP, Ross S, Bhatt S, et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry, 79(10):953–962. PMID 36001306. https://pubmed.ncbi.nlm.nih.gov/36001306/
7. Health Canada. Information on requesting access to psychedelic-assisted psychotherapy through the case-by-case authorization pathway. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
8. Government of Canada. 9-8-8 Suicide Crisis Helpline. https://988.ca/

---

Related articles

• How Psilocybin-Assisted Psychotherapy Works

---

Last updated: 2026-05-27. This article is reviewed every 6 months.